Regional Growth and Demand of Atherectomy Devices Market:
North America is expected to account for the largest share of the Atherectomy Devices Market in 2017, followed by Europe. Factors such as increasing availability of reimbursements for atherectomy devices, growing adoption of atherectomy devices among medical professionals, large patient population of peripheral & coronary artery diseases, and growing number of clinical trials are driving the growth of the North American atherectomy devices market. Asia Pacific is expected to register the highest growth rate during the forecast period. This can be attributed to the increasing prevalence of target diseases, increasing healthcare expenditure, cost-effective (owing to the increase in localized manufacturing and strengthening of distribution networks of key product manufacturers), and rising awareness among surgeons related to the benefits offered by atherectomy systems (less revascularization rates, high efficacy, short procedural time). The global atherectomy devices market accounted is projected to reach $1.45 Billion by 2022 from $1.02 Billion in 2016, at a CAGR of 6.1%. Get Crucial Industry Revenue Growth Insights | Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=133112140 Applications of Atherectomy Devices Market: 1. Peripheral Vascular Applications 2. Cardiovascular Applications 3. Neurovascular Applications The peripheral vascular applications segment accounted for the major share of the market owing to the significant availability of clinical evidence to support the therapeutic efficacy of atherectomy in PVD treatment and growing patient preference for minimally invasive surgical procedures. Global Market Growth Opportunities: 1. Increasing Number of Research Activities in the Field of Atherectomy 2. Increasing Healthcare Expenditure Across Emerging Markets Atherectomy Devices Market by Products: The directional atherectomy devices segment accounted for the largest share of the market. It is also expected to register the highest CAGR during the forecast period. This can be attributed to clinical benefits offered (such as lack of barotrauma, less risk of neointimal hyperplasia, immediate change of bypass site, and availability of differently sized instruments to enable atherectomy in blood vessels) and ongoing technological advancements in the field of directional atherectomy. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=133112140 Leading Players in Atherectomy Devices Market: Major players operating in the market are Medtronic (Ireland), Philips (Netherlands), Boston Scientific (US), and Cardiovascular Systems (US). Other prominent players present in this market include Straub Medical (Switzerland), BIOTRONIK (Netherlands), C.R. Bard (US), and Avinger (US).
0 Comments
Medtronic is the leading provider of digital diabetes management solutions across the globe. The company offers a portfolio of health information exchange solutions, clinical decision support solutions, and telehealth solutions and services to meet the needs of patients and physicians working in the areas of diabetes management. The company focuses on developing integrated devices that enable data sharing between devices, patients, care providers, and healthcare professionals to help generate actionable insights.
Roche is one of the leading providers of blood glucose monitoring systems in the digital diabetes management market. The company offers digital glucometers, diabetes management applications, and data management software. To maintain its position in this market, the company focuses on expanding its product portfolio through organic and inorganic strategies, such as product launches, collaborations, partnerships, agreements, and acquisitions. The global digital diabetes management market is projected to reach USD 19.9 billion by 2024 from USD 6.8 billion in 2019, at a CAGR of 23.8%. The growth of this market is mainly driven by the rising prevalence of diabetes, increasing focus on the development and adoption of digital platform for diabetes, and technological advancements. Know Crucial Industry Insights | Download PDF Brochure Now: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144725893 The global digital diabetes management industry in North America is expected to grow at the highest CAGR during the forecast period. This is due to the growing demand for technologically advanced solutions such as closed-loop systems, high adoption of remote online coaching services for diabetes management, high adoption of connected diabetes management devices and apps, favorable reimbursement policies, increased acceptance of digital diabetes solutions from payers, rising awareness on self-diabetes management and government initiatives to promote digital health in the region. Prominent players in the global digital diabetes management market are Medtronic (Ireland), B. Braun (Germany), Dexcom (US), Abbott Laboratories (US), Roche Diagnostics (Switzerland), Insulet Corporation (US), Tandem Diabetes Care (US), Ascensia Diabetes Care (Switzerland), LifeScan (US), Tidepool (US), AgaMatrix (US), Glooko Inc. (US), and DarioHealth (Israel). Recent Development in Global Digital Diabetes Management Market: 1. In 2018, Medtronic plc acquired Nutrino Health Ltd. (Israel). This acquisition strengthened Metronic’s CGM and industry-leading hybrid closed-loop systems portfolio in the digital diabetes management market. 2. In 2018, Roche Diagnostics signed a partnership with Wellthy Therapeutics Private Limited (India) that offers an artificial intelligence-based digital diabetes coaching solution for users of the Accu-Chek Active system. 3. In 2017, Medtronic launched the MiniMed 670G Insulin Pump System 4. In 2017, Dexcom opened a new head office in Canada to enhance customer experience and support Canadian diabetes patients. Critical Questions Explained in The Research: 1. Where will all these developments take the industry in the medium to long-term? 2. Who are the major end users of digital diabetes management apps? 3. Which are the major digital diabetes management products? 4. Which technologies are mainly used for digital diabetes management? Get Expert Market Analysis | Download Sample Report Now: https://www.marketsandmarkets.com/requestsampleNew.asp?id=144725893 According to a new market research report "Angiographic Catheters Market by Application (Coronary, Endovascular, Neurology and Oncology), Geography (North America, Europe, Asia Pacific and Row), End-User Analysis (Reusage Scenario, Purchase Pattern) and Competitive Scenario - Global Forecast to 2022", the global market is projected to reach USD 1,402.8 Million by 2022 from USD 980.9 Million in 2017, at a CAGR of 7.4%.
The Angiographic Catheters Market is primarily driven by the rising incidence of coronary artery diseases across the globe. Further, increasing demand for angiographic catheters in various applications such as chemoembolization, awareness regarding various diseases such as CVDs, and preference for minimally invasive surgeries are also driving the growth of this market. Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1219487 Based on application, the coronary segment is projected to register the highest growth rate during the forecast period Based on application, the market is segmented into coronary, endovascular, neurology, oncology and other applications (such as lungs, urology, and gastroenterology). The coronary segment is expected to grow at the highest CAGR during the forecast period. Factors driving the growth of this segment include the increasing incidence of cardiovascular disease, demand for catheter-based angiography in coronary treatments and awareness regarding various diseases mainly in developing countries. Browse and in-depth TOC on "Angiographic Catheters Market" 76 – Tables 34 - Figures 113 – Pages Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1219487 Europe commanded the largest share of the market during the forecast period Based on region, the Angiographic Catheters Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). Europe dominated the Angiographic Catheters Market in 2017. This is mainly due to the large patient population throughout the region. The growing demand for minimally invasive surgeries is also driving the growth of this market. Key players operating in the Angiographic Catheters Market include Medtronic (US), Boston Scientific (US), Terumo Medical (Japan), Cardinal Health (US), and Merit Medical System (US). Q-TOF Mass Spectrometry Market | Demand and Growth in Biotech & Pharmaceutical Applications1/20/2020 The global downstream processing market is poised to reach $22.03 Billion by 2021 from $10.32 Billion in 2016, at a CAGR of 16.4%. The growth of this market is propelled by the increasing demand for biopharmaceuticals and increasing R&D expenditure in the biopharmaceutical industry. Emerging markets such as Asia-Pacific provide new growth opportunities to players in the market.
The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. Countries like China, Japan, India, and South Korea, are expected to drive the demand for downstream processing products in the coming years. Also, growth in these markets will be fueled by significant investments by key market players, increasing government support, developing R&D infrastructure, and growing expertise and academic excellence. North America is the world’s largest pharmaceutical market and a leader in biopharmaceutical research. North America (comprising the U.S. and Canada) accounted for the largest share of the global market in 2016. Rising quality requirements have emphasized the need for advanced bioproduction technology in this region. Downstream Processing Market, by Product: 1. Chromatography Columns and Resins 2. Filters 3. Membrane Adsorbers 4. Single-use Products 5. Other Products (Consumables and Accessories) On the basis of product, the market is classified into chromatography columns and resins, filters, membrane adsorbers, single-use products, and other products. In 2016, the chromatography columns and resins segment accounted for the largest share of the market. The constant need for newer and different types of columns and resins is likely to fuel market growth. Get Crucial Industry Insights: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=73180930 Based on application, the downstream processing market is categorized into monoclonal antibody (mAbs) production, vaccine production, insulin production, immunoglobulin production, erythropoietin production, and other applications. In 2016, the vaccine production segment accounted for the largest share of the market. Technological advancement in the downstream purification technology to develop high-quality products such as Vaccines at lower costs is expected to drive the growth of this segment. Key Players in Downstream Processing Market: The Downstream Processing Market is dominated by established players such as Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.S.), Sartorius Stedim Biotech S.A. (France), Merck Millipore (Germany), and Danaher Corporation (U.S.). Downstream Processing Market, by End User: 1. Biopharmaceutical Manufacturers 2. Contract Manufacturing Organizations (CMOs) Based on end user, the market is segmented into biopharmaceutical manufacturers and contract manufacturing organizations (CMOs). In 2016, the biopharmaceutical manufacturers segment accounted for the largest share of the market. The increasing demand for biopharmaceuticals among the aging population is expected to accelerate the growth of the biopharmaceutical manufacturers’ end-user segment. Know more Insights: https://www.marketsandmarkets.com/Market-Reports/downstream-processing-market-73180930.html Growth in the mass spectrometry market is primarily driven by factors such as government initiatives for pollution control and environmental testing, increasing spending on pharmaceutical R&D across the globe, government regulations on drug safety, growing focus on the quality of food products, increase in crude and shale gas production, and technological advancements in mass spectrometers.
The mass spectrometry market is expected to grow from $4.6 billion in 2019 to $6.3 billion by 2024, at a CAGR of 6.7%. Get More Crucial Insights of Market: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=437 Pharmaceutical & biotechnology are the primary application areas of the global mass spectrometry market: Mass spectrometry is widely used for accurate analysis of small as well as large molecules in pharmaceuticals, forensic & clinical research, and other areas. The market is segmented into pharmaceutical & biotechnology applications, environmental testing, food & beverage testing, petrochemical applications, and other applications based on use. The pharmaceutical & biotechnology applications segment estimated to command the largest share of the market in 2019, and this segment is also projected to register the highest CAGR owing to the rise in pharmaceutical biosimilars phytopharmaceuticals and regenerative medicine along with the growing research in proteomics and metabolomics. The Hybrid Mass Spectrometry: The hybrid mass spectrometry segment is expected to witness the fastest growth during the forecast period. Advantages offered by hybrid mass spectrometers, such as rapid and high-resolution testing abilities with more accurate and precise results, are increasing its adoption. Consequently, the demand for mass spectrometry devices for high throughput screening is also growing. North America and APAC to Dominate The Global Mass Spectrometry Market: North America held the largest share of the market in 2018 and is projected to continue to do so during the forecast period. Factors such as the growing funding for research and government initiatives in the US, widespread usage of mass spectrometry in the metabolomics and petroleum sector, and CFI funding towards mass spectrometry projects in Canada are driving the North American market. While North America is expected to dominate the global mass spectrometry market in 2019, the Asia Pacific region is expected to register the highest CAGR during the forecast period. The high growth in this region can be attributed to the numerous expansions and collaborations by key players in China, a significant amount of funding for mass spectrometry in Japan, and strict environmental monitoring regulations in India. Get Expert Analysis and Insights of Global Market | Download Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=437 Key Questions Answered in This Report: 1. Which of the platform segments will dominate the mass spectrometry market in the next five years? 2. What are the upcoming technologies in the market? 3. Which application segment will dominate the market in the next five years? 4. Emerging countries have immense opportunities for the growth and adoption of mass spectrometry, will this scenario continue in the next five years? Key Players: The major players operating in the mass spectrometry market include SCIEX (US), Agilent Technologies (US), Thermo Fisher Scientific (US), Waters Corporation (US), and Shimadzu Corporation (Japan). The other players in this market include PerkinElmer (US), Bruker (US), Analytik Jena (Germany), JEOL (Japan), Rigaku (Japan), DANI Instruments (Italy), LECO (US), Hiden Analytical (UK), Kore Technology (UK), Extrel CMS (US), MassTech (US), AMETEK Process Instruments (US), MKS Instruments (US), Advion (US), and FLIR Systems (US). How The Global Digital Diabetes Management Market to Revolutionize the Global Healthcare Industry.
The growth of this market is mainly driven by the rising prevalence of diabetes, increasing focus on the development and adoption of digital platform for diabetes, and technological advancements. The Digital Diabetes Management Industry to Offer $19.9 billion Growth Globally. Know more, Download PDF Brochure Now: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144725893 The wearable devices segment is expected to account for the largest share of the digital diabetes management market: The large share of the market is mainly due to factors such as the increasing number of regulatory approvals for CGM systems; technological advancements such as closed-loop pump systems, smart insulin patches, and other pipeline devices; and the growing adoption of smart insulin pumps and insulin patches for self-insulin delivery in diabetes management. The self/home healthcare segment accounted for the largest share of the digital diabetes management market: The large share of this segment can mainly be attributed to technological advancements and a shift toward home care and self-management of diabetes. North America is expected to grow at the highest CAGR during the forecast period The global digital diabetes management market in North America is expected to grow at the highest CAGR during the forecast period. This is due to the growing demand for technologically advanced solutions such as closed-loop systems, high adoption of remote online coaching services for diabetes management, high adoption of connected diabetes management devices and apps, favorable reimbursement policies, increased acceptance of digital diabetes solutions from payers, rising awareness on self-diabetes management and government initiatives to promote digital health in the region. Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=144725893 Medtronic is the leading provider of digital diabetes management solutions across the globe. The company offers a portfolio of health information exchange solutions, clinical decision support solutions, and telehealth solutions and services to meet the needs of patients and physicians working in the areas of diabetes management. The company focuses on developing integrated devices that enable data sharing between devices, patients, care providers, and healthcare professionals to help generate actionable insights. Roche is one of the leading providers of blood glucose monitoring systems in the digital diabetes management market. The company offers digital glucometers, diabetes management applications, and data management software. To maintain its position in this market, the company focuses on expanding its product portfolio through organic and inorganic strategies, such as product launches, collaborations, partnerships, agreements, and acquisitions. For instance, in 2017, the company acquired mySugr GmbH, which helped it to expand its product portfolio in the area of diabetes management apps. Also, in 2018, Roche partnered with various companies such as Wellthy Therapeutics Private Limited (India), Ieso Digital Health Ltd. (UK), and Care Innovations Ltd. (US) to integrate its existing portfolio and develop solutions for global, personalized management of diabetes by connecting patients and healthcare professionals to better control the disease. The major factors driving the growth of this market are rising incidence of chronic diseases, rising geriatric population, and increasing demand for minimally invasive surgeries. However, new players in the interventional radiology products market face significant entry barriers; this is a key challenge in the market.
According to a new market research report "Interventional Radiology Products Market by type (Stents, Catheters, IVC Filter, Accessories), Procedure Type (Angioplasty, Angiography, Biopsy, Thrombolysis, Embolization), Applications (Oncology, Cardiology, Urology & Nephrology) - Forecast to 2021", published by MarketsandMarkets. The global market is expected to reach USD 8.02 Billion by 2021 from USD 6.35 Billion in 2016, at a CAGR of 4.8% from 2016 to 2021. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=67681703 Key players in the interventional radiology products market include Abbott Vascular (U.S.), Boston Scientific Corporation (U.S.), Medtronic plc (Ireland), Cardinal Health (U.S.), B. Braun Melsungen AG (Germany), C.R Bard (U.S.), Biosensor International Group Ltd. (Singapore), Stryker Corporation (U.S.), Terumo Corporation (Japan), and Cook Medical Inc. (U.S.). Based on type, the market is segmented into stents, catheters, IVC filters, hemodynamic flow alteration devices, angioplasty balloons, thrombectomy systems, embolization devices, biopsy needles, and accessories. In 2016, the stents segment is expected to dominate the global interventional radiology products industry. The key factors driving the growth of the interventional radiology stents market are the growing geriatric population and increasing incidence of cardiovascular diseases around the world. Browse in-depth TOC on "Interventional Radiology Products Market” 79 – Tables 37 - Figures 144 - Pages Based on procedure, the market is segmented into angioplasty, angiography, embolization, thrombolysis, biopsy & drainage, vertebroplasty, nephrostomy, and other applications. In 2016, the angiography segment is expected to account for the largest share of this market. The growing demand for minimally invasive procedures and rising geriatric population are the key factors driving market growth in this segment. Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=67681703 Based on region, the global interventional radiology products market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2016, North America is expected to account for the largest share of the market. The rising incidence of chronic diseases (CVD), the increasing demand for minimally invasive procedures, and availability of reimbursement for minimally invasive products in this region are the major factors contributing to the growth of this market. Oligonucleotide Synthesis : An Emerging Market with Promising Future in Pharma and Biotech Industry11/4/2019 What is the future growth analysis of global Oligonucleotide Synthesis Market?
The global oligonucleotide synthesis market is projected to reach USD 8.2 billion by 2024 from USD 4.3 billion in 2019, at a CAGR of 13.7% What are key factors driving growth of global Oligonucleotide Synthesis Market? This market is experiencing significant growth due to the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques. What the growth opportunities are in Oligonucleotide Synthesis Market? 1. Untapped Emerging Markets 2. Increasing Use of Synthesized Oligos in Molecular Diagnostics 3. Rise in Venture Capital Investments Know more, Download PDF Brochure Now: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350 Global Market Segmentation: In the current market scenario, there is a growing demand for Oligonucleotide Synthesis. The market has been categorized based on the product, type, application, and region. The synthesized oligos market, by product, is segmented into oligonucleotide-based drugs, primers, probes, large-scale synthesized oligos, intermediate-scale synthesized oligos, and linkers and adaptors. Of these, oligonucleotide-based accounted for over 50% of the synthesized oligos market share in 2018. This segment is also estimated to grow at the highest CAGR during the forecast period due to the increasing demand for oligonucleotide-based drugs and the influx of new customers in the oligo drug development arena. Based on end user, the oligonucleotide synthesis market is segmented into academic research institutes, diagnostic laboratories, pharmaceutical & biotechnology companies, and hospitals. Hospitals contributed to the highest revenue generated among these segments within the market in 2018. The significant number of inpatient and outpatient visits in hospitals coupled with the high requirement of oligonucleotide drugs to cater to the demand from the vast patient pool suffering from diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and hepatic veno-occlusive disease, is driving the market growth in the segment. Geographic Growth Analysis: The global oligonucleotide synthesis industry is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America was the largest market for share, followed by Europe. Moreover, North America is estimated to register the highest CAGR during the forecast period primarily due to the increasing R&D activities and the growing number of oligonucleotide-based drugs/therapies being approved by the FDA. Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=200829350 Key Players In Global Oligonucleotide Synthesis Market: The prominent players operating in oligonucleotide synthesis market include Agilent Technologies, Inc. (US), ATDBio Ltd. (UK), Bio-Synthesis, Inc. (US), BioAutomation Corporation (US), LGC Biosearch Technologies (US), Biogen International (US), Sarepta Therapeutics (US), Eurofins Genomics (Germany), Eurogentec (Belgium), GeneDesign, Inc. (Japan), GE Healthcare (US), GenScript, Inc. (US), Integrated DNA Technologies (IDT, US), Nitto Denko Avecia, Inc. (US), Sarepta Therapeutics (US), Thermo Fisher Scientific, Inc. (US), TriLink BioTechnologies (US), and Sigma-Aldrich Corporation (US) (a part of Merck KGAA). Sigma-Aldrich Corporation (US) was one of the leading players in the oligonucleotide synthesis market in 2018. The company is innovation-centric and focuses on R&D to develop and introduce new enhanced products in the market. It is a leading supplier of custom DNA and RNA oligonucleotides for the life sciences research community in North America. Thermo Fisher Scientific is another leading player in the market. The company’s strong brand recognition and extensive product portfolio in this market are its key strengths. To maintain its leading position in the market, the company adopts organic as well as inorganic growth strategies such as expansions and acquisitions. |
AuthorHere you will find the latest and updated market research, new trends of global Healthcare Industry |